Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — Q3 2024 Earnings Presentation
13 slides from Heartbeam's earnings presentation, Nov 7, 2024
Slide 1: The Future of Cardiac Care
The Future of Cardiac Care Third Quarter 2024 Financial Results Conference Call NASDAQ: BEAT NOVEMBER 7, 2024
Slide 2: Disclaimers
Third Quarter 2024 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial position
Slide 3: Agenda: On the Call Today
Third Quarter 2024 Financial Results Conference Call Agenda: On the Call Today: COMPANY OVERVIEW REGULATORY UPDATES MANAGEMENT TEAM COMPANY UPDATES FINANCIAL RESULTS Rob Eno Branislav Vajdic, PhD Tim Cruickshank CEO President & Founder CFO MILESTONES AND CLOSING SUMMARY 3
Slide 4: HeartBeam: A New Generation in Cardiac Care
Third Quarter 2024 Financial Results Conference Call HeartBeam: A New Generation in Cardiac Care Unique IP-enabled Market Opportunity Roadmap with 3 Derisked through near- Clear Go To Market disruptive technology large and growing Clear Focus Areas term milestones Strategy First ever cable- Position
Slide 5: Fundamental, IP Protected Advances Enable HeartBeam's 12L Technology
Third Quarter 2024 Financial Results Conference Call Fundamental, IP Protected Advances Enable HeartBeam’s 12L Technology 3 Dimensions IP Breakthrough Personalized Collects signals in 3 Credit card-sized device with Signals from 3 dimensions dimensions, capturing the novel resistive network train He
Slide 6: FDA Clearance Will be a Major Milestone
Third Quarter 2024 Financial Results Conference Call FDA Clearance Will be a Major Milestone • HeartBeam 510(k) application remains under active FDA review STATUS • Responded to FDA’s questions and working through remaining clarifications • Interactive process: FDA is engaged and responding • Antici
Slide 7: Management Team Updates
Third Quarter 2024 Financial Results Conference Call Management Team Updates Planned evolution in preparation for US Commercialization Rob Eno Appointed Dr. Branislav Vajdic Tim Cruickshank Dr. Lance Myers Appointed Chief Executive Officer Appointed President Appointed CFO Chief AI Scientist October
Slide 8: Significant Body of Evidence on HeartBeam's Groundbreaking Technology
Third Quarter 2024 Financial Results Conference Call Significant Body of Evidence on HeartBeam’s Groundbreaking Technology Strengthening evidence base per indication for use 500+ PATIENTS IN HeartBeam AI + Equivalence to CLINICAL STUDIES Vector ECG for 12L ECG for Complex 9 Arrhythmia Arrhythmias Fu
Slide 9: HeartBeam Named Winner at 2024 Digital Health Hub Awards
Third Quarter 2024 Financial Results Conference Call HeartBeam Named Winner at 2024 Digital Health Hub Awards • HeartBeam named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards • Company received top honors in the “Home Health Diagnostic” category • Selected among thousands of en
Slide 10: Financials
Third Quarter 2024 Financial Results Conference Call Financials Focused on financial discipline to deliver on goals while minimizing cash burn $ in Thousands Quarter Ended September 30, 2024 2023 Operating Expenses: Cash Shareholder General & Administrative $2,176 $2,114 Burn Support Research & Deve
Slide 11: Innovation Paving Way for Commercialization Launch
Third Quarter 2024 Financial Results Conference Call Innovation Paving Way for Commercialization Launch Near-term milestones creating significant momentum 2024 2025 Regulatory Clinical Commercial HeartBeam System FDA Clearance Foundational Clearance VALID-ECG FDA Clearance 12L Synthesis Software Enr
Slide 12: Closing Summary
Third Quarter 2024 Financial Results Conference Call Closing Summary • Progressing toward foundational FDA clearance Preparing for • Early Access Program to provide key insights Commercialization • Management Team updated as part of planned evolution Strengthening • Two additional studies to be pres
Slide 13: Q&A
Q&A Company Investor Relations Tim Cruickshank Chris Tyson CFO Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050